Introduction
Tumor antigen-specific CD4 þ helper T cells play important roles in the induction and maintenance of antitumor immune responses. The roles of antigen-specific CD4 þ T cells include providing help to CD8 þ T cells during the primary and secondary immune responses, inducing the activation/maturation of antigen-presenting cells (APC), producing cytokines that are essential for differentiation or maintenance of longlasting T-cell responses, and activating B cells to produce tumor antigen-specific antibodies (1, 2) . In addition, immune-potentiating cytokines from CD4 þ T cells may help other immune cells to overcome the actions of immunosuppressive factors (3, 4) . In the classical view of antigen presentation, intracellular and extracellular proteins are presented to CD8 þ and CD4 þ T cells via the MHC class I (MHC-I) and MHC class II (MHC-II) pathways, respectively (5, 6) . Therefore, although tumor antigen-specific CD8 þ T cells efficiently recognize intracellular antigen-expressing cancer cells, the activation of tumor antigen-specific CD4 þ T cells generally requires professional APCs that take up and cross-present tumor antigen proteins. Recently, accumulating evidence has demonstrated that APCs at the tumor microenvironment are frequently immunosuppressive and lead to unresponsiveness of T cells (7, 8) . The absence of functional APCs that crosspresent tumor antigen protein to CD4 þ T cells may limit CD4
help at the local tumor sites and could partly explain the rapid exhaustion of tumor antigen-specific CD8 þ T cells. An alternative path by which tumor antigen-specific CD4 þ T cells could overcome the requirement for APCs within the tumor microenvironment is direct recognition of tumors.
In contrast with murine cancer cells, many types of human cancers constitutively express MHC-II or are induced to express MHC-II in an IFN-g-dependent manner (9) . Tumor antigen-specific CD4 þ T cells that directly recognize cancer cells have been described (10) (11) (12) (13) ; however, the mechanisms relating to antigen specificity and antigen processing that the CD4 þ T cells use for direct tumor recognition are unknown.
Although several distinct nonclassical antigen presentation pathways have been identified for the presentation of intracellular proteins on MHC-II of professional APCs (14) (15) (16) (17) , it is not clear whether these pathways are functional in cancer cells for MHC-II presentation of intracellular tumor antigens. Recently, we have identified a novel nonclassical antigen presentation pathway for the presentation of intracellular NY-ESO-1 to HLA-DRB1 Ã 01 (DR01)-restricted NY-ESO-1-specific CD4
þ T cells by cancer cells (18) . Two DR01-restricted (20) . In the present study, we identified the unique peptide specificity and antigen-processing pathways that allow direct recognition of cytoplasmic protein presented by MHC-II on cancer cells by the human CD4 þ T-cell subset. Because of the frequent expression of DP04 (present in 43%-70% of Caucasians; ref. 21) , our observations will be useful for the development of novel immunotherapies that harness direct tumor-recognizing ability of CD4 þ T cells.
Materials and Methods

NY-ESO-1-specific T cells and cell lines
Peripheral blood mononuclear cells (PBMC) and tumor tissues were obtained from patients with epithelial ovarian cancer under an approved protocol from the institutional review board at Roswell Park Cancer Institute (Buffalo, NY). NY-ESO-1 expression in tumor tissues was determined by immunohistochemistry and/or semiquantitative reverse-transcription PCR (RT-PCR), and anti-NY-ESO-1 antibody response in serum was analyzed by ELISA, as described previously (22 Melanoma cell lines and EBV-transformed B-cell lines were from our cell bank. Establishment and characterization of SK-MEL-37 clones expressing ICP47 have been described (18) . Cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), penicillin, streptomycin, and L-glutamine.
Generation of monocyte-derived dendritic cells
CD14 þ monocytes were magnetically isolated from DP04 þ healthy donor PBMCs using anti-CD14 microbeads (Miltenyi Biotech). Monocytes were cultured for 6 days in RPMI-1640 medium supplemented with 10% FCS, penicillin, streptomycin, and L-glutamine in the presence of 1,000 U/mL granulocyte macrophage colony-stimulating factor (GM-CSF), and 20 ng/mL IL-4 (CellGenix).
Pretreatment of target cells
Synthetic peptides were pulsed on target cells overnight at 10 mmol/L unless otherwise specified. Recombinant NY-ESO-1 protein was expressed in Escherichia coli and purified by a standard method. NY-ESO-1 protein was pulsed overnight on SK-MEL-29 at a concentration of 10 mg/mL or on dendritic cells (DC) at different concentrations. Peptide or recombinant protein-pulsed and -unpulsed target cells were extensively washed before coculture with T cells. To determine HLA restriction of T-cell recognition, target cells were treated with 10 mg/mL anti-HLA-ABC monoclonal antibody (W6/32; eBioscience) and/or 20 mL of anti-HLA-class II antibody supernatant for 1 hour before addition of T cells. Culture supernatants from anti-DP (B7/21), anti-DQ (SPV-L3), and anti-DR (L243) hybridomas were used as sources for anti-HLA-class II antibodies. In some experiments, target cells were pretreated with 1,000 U/mL (50 ng/mL) IFN-g (Peprotech) for 2 days. Treatment of SK-MEL-37 with inhibitors for the antigen-processing pathway was performed as described (18) . All inhibitors were water soluble except for lactacystin and epoxomicin, which were dissolved in dimethyl sulfoxide. After treatment, SK-MEL-37 was fixed with 1% paraformaldehyde, quenched with glycine, and extensively washed in PBS and culture medium. For mRNA electroporation, EBV-transformed B-cell line (1 Â 10 6 ) was mixed with 5 mg in vitro-transcribed mRNA (Ambion) in 50 mL X-Vivo15 (Lonza) and was applied at a pulse of 1.25 kV/cm for 700 msec using the ECM 830 Electroporation system and cuvettes (Harvard apparatus-BTX). Cells were incubated overnight in a culture medium until T-cell recognition assays. Electroporation of SK-MEL-37 with synthetic siRNA (Integrated DNA Technologies or Origene) was performed as described (18) .
Intracellular cytokine staining
Brefeldin A (BFA) and monensin were added 2 hours after coculturing T cells and target cells. After 6 hours of coculture, cells were fixed with 2% paraformaldehyde and permeabilized using FIX & PERM reagents (Invitrogen-CALTAG) according to the manufacturer's instructions (20) . Cytokine production was assessed by intracellular staining measured by flow cytometry. Antibodies were obtained from BD Biosciences.
ELISPOT assay
The number of IFN-g-secreting antigen-specific T cells was assessed by ELISPOT assays as described (20) . The dark-violet spots were counted by an automated ELISPOT reader (Zeiss or CTL). 
Measurement of cytokines
Statistical analyses
Error bars in the graphical data represent means AE SD. All in vitro experiments were performed at least in duplicate. P values of less than 0.05 were considered statistically significant by the Student t test. All statistical analyses were performed using Prism 5 software (GraphPad Software).
Results
Characterization of tumor recognition by CD4
þ T cells
We established DP04-restricted NY-ESO-1 157-170 peptidespecific CD4 þ T-cell clones from a patient with ovarian cancer who was repeatedly vaccinated with DP04-binding NY-ESO-1 157-170 peptide (20) . For this patient, NY-ESO-1 157-170 peptide-specific CD4 þ T cells were not detected in prevaccine
PBMCs, but were significantly expanded by the vaccinations (data not shown). One of 4 established NY-ESO-1-specific (20) . The other 3 clones showed no direct reactivity against the melanoma cell line. To gain an insight into the different ability in direct tumor recognition by CD4 þ T cells, we characterized target recognition by representative tumor-recognizing CD4 þ T-cell clone (TR-CD4) and nontumor-recognizing CD4 þ T-cell clone (NTR-CD4). Whereas TR-CD4 specifically recognized NY-ESO-1-expressing DP04 þ melanoma cell lines, all DP04 þ melanoma cell lines were recognized by both TR-CD4 and NTR-CD4 after pulsing with the NY-ESO-1 157-170 vaccine peptide ( Fig. 1A and B) . In subsequent experiments, we selected the NY-ESO-1-expressing melanoma cell line, SK-MEL-37 (SK37) because (i) DR01 þ DP04 þ SK37 was extensively characterized for the recognition by DR01-restricted NY-ESO-1-specific CD4 þ T cells in our previous study (18) ; and (ii) SK37 was efficiently recognized by A02-restricted NY-ESO-1-specific CD8 þ T-cell clone (18) . SK37 expressed both HLA class I and class II molecules and CD40 but no costimulatory molecules, CD80 and CD86 ( Supplementary Fig. S1 ). Recognition of SK37 by TR-CD4 was specifically inhibited by anti-HLA-DP blocking antibody, demonstrating DP04-restricted target cell recognition (Fig. 1C) . As expected, recognition of SK37 by control NY-ESO-1-specific A02-restricted CD8 þ T cells was inhibited by anti-HLA class I blocking monoclonal antibody. Electroporation of NY-ESO-1-specific siRNA, which efficiently silenced NY-ESO-1 expression in SK37, significantly reduced the recognition by TR-CD4 (Fig. 1D ), supporting the NY-ESO-1 specificity in the direct tumor recognition by TR-CD4. We next asked whether the differential ability to recognize NY-ESO-1-expressing cancer cells by TR-CD4 and NTR-CD4 indicates differences in the recognition of intracellular NY-ESO-1 protein in these cells. The NY-ESO-1-non-expressing DP04 
Determination of minimal epitopes
We investigated the mechanism for the differential recognition of intracellular NY-ESO-1 by TR-CD4 and NTR-CD4 in terms of peptide recognition by T-cell receptor (TCR). The titration curves for TR-CD4 and NTR-CD4 to recognize the vaccine peptide, NY-ESO-1 157-170 , were similar ( Fig. 2A) . In addition, two long 20-mer peptides, NY-ESO-1 151-170 and NY-ESO-1 161-180 , were similarly recognized by TR-CD4 and NTR-CD4 (Fig. 2B and C) . Recognition of naturally processed exogenous NY-ESO-1 protein by TR-CD4 and NTR-CD4 was tested.
TR-CD4 more efficiently recognized NY-ESO-1 protein-pulsed monocyte-derived DCs than NTR-CD4 (Fig. 2D) , which potentially explains the more efficient tumor recognition by TR-CD4. To investigate the mechanism(s) by which TR-CD4 recognizes cancer cells, short overlapping vaccine peptides were tested for recognition by TR-CD4 and NTR-CD4 (Fig. 2E ). In contrast with the similar recognition of 10-mer peptide NY-ESO-1 160-169 by TR-CD4 and NTR-CD4, recognition of 9-mer peptide NY-ESO-1 161-169 by NTR-CD4 was significantly reduced, whereas it was fully recognized by TR-CD4 (Fig. 2E) . In addition, the recognition of 8-mer peptide NY-ESO-1 161-168 was more efficient by TR-CD4 than by NTR-CD4 (Fig. 2E ). There is a significant difference in the titration curves for the recognition of NY-ESO-1 161-169 peptide by TR-CD4 and NTR-CD4 (Fig. 2F) . The recognition of NY-ESO-1 161-169 by NTR-CD4 was barely detectable at 10 nmol/L, whereas the recognition by TR-CD4 was still detectable at 0.01 nmol/L concentration. Taken together, these results indicate that naturally processed intracellular and extracellular NY-ESO-1 proteins are loaded on DP04 in a manner that is preferentially recognized by TR-CD4 rather than NTR-CD4.
We searched for the presence of TR-CD4 in DP04 þ ovarian cancer patients who did not receive peptide vaccination but had spontaneous NY-ESO-1-specific serum antibody. As we found previously that ovarian tumors are highly enriched with NY-ESO-1-specific CD8 þ T cells (24) , ovarian TILs were assessed to increase the possibility of detecting NY-ESO-1-specific T cells. We tested TILs from 4 patients and found NY-ESO-1-specific CD4 þ T cells that recognize both NY-ESO-1 161-169 and SK37 in one TIL-derived NY-ESO-1-specific CD4 þ T-cell line (Fig. 3A) ,
indicating that TR-CD4 is not induced only by synthetic peptide vaccinations but is also induced spontaneously by the NY-ESO-1 protein expressed in cancer cells and infiltrates in the tumor sites. Next, we tested whether freshly isolated ovarian cancer cells from patients can stimulate TR-CD4 ex vivo when they express NY-ESO-1 and DP04. Single-cell suspensions of 5 NY-ESO-1-expressing and 5 NY-ESO-1-negative tumor specimens from DP04 þ patients were tested for recognition by TR-CD4 and NTR-CD4. Notably, TR-CD4 but not NTR-CD4 specifically produced high amounts of IFN-g when cocultured with 2 of 5 NY-ESO-1 þ ex vivo ovarian cancer cells (Fig. 3B) . Together, the 
Antigen-processing pathway of endogenous MHC-II presentation
To elucidate the antigen-processing pathway for the NY-ESO-1/DP04 epitope in SK37, we treated SK37 with inhibitors of antigen processing at doses that did not inhibit MHC-II exogenous peptide presentation by SK37 (18) . As shown in Fig. 4A , treatment of SK37 by a proteasome inhibitor, epoxomicin, substantially inhibited the recognition by TR-CD4. The inhibitory effect by another proteasome inhibitor, lactacystin, was negligible, indicating that generation of the peptide recognized by TR-CD4 is dependent on the chymotrypsin-like activity of the proteasome (25) . Treatment of melanoma cell lines with IFN-g did not inhibit recognition by TR-CD4 (Supplementary Fig. S2 ), indicating that both standard-and immuno-proteasomes similarly processed the epitope. In addition, two endosomal/lysosomal protease inhibitors, chloroquine and leupeptin, significantly inhibited the presentation, suggesting the role of the proteases in antigen processing and/or loading on MHC-II in endosomes/lysosomes (Fig.  4B) . As the generation of MHC-II-binding peptide is dependent on proteasome, which is generally involved in the generation of MHC-I-binding peptides, we investigated the involvement of other enzymes that were reported to be involved in the generation of MHC-I-binding peptides. As shown in Fig. 5A , AAF-CMK that inhibits tripeptidyl peptidase II (TPPII; refs. 26, 27) partially inhibited the presentation at the high dose, whereas aminopeptidase inhibitor (bestatin; refs. [28] [29] [30] and metalloprotease inhibitor (1,10-phenanthroline; ref. 31) had no effect. TPPII is a cytosolic peptidase that trims peptides generated by the proteasome. The involvement of TPPII in addition to the cytosolic proteasome in the endogenous MHC- II presentation supports the cytosolic degradation of intracellular NY-ESO-1. In addition, SK37 clones expressing viral ICP47, which inhibits transporter-associated with antigen-processing (TAP)-mediated peptide transport, showed reduced stimulatory activity compared with parental SK37, indicating a role for TAP-mediated peptide transport into the endoplasmic reticulum during the presentation (Fig. 5B) .
Next, we investigated the involvement of nonclassical antigen-presentation pathways for the presentation of intracellular protein to CD4 þ T cells by professional APCs and B cells. We found that macroautophagy and chaperone-mediated autophagy were not involved in this presentation by treatment with macroautophagy inhibitor, 3-methyladenine, and by siRNAmediated silencing of LAMP-2, respectively ( Fig. 6A and B; refs. 14, 16). Intracellular viral protein has been presented on recycled MHC-II, which is efficiently inhibited by primaquine (15, 32) . As shown in Fig. 6C , treatment with primaquine significantly inhibited the presentation to TR-CD4, indicating the involvement of endosomal recycling, presumably the MHC-II molecules. No significant inhibition by cycloheximide and brefeldin A, which inhibit new protein synthesis and vesicular trafficking, respectively, supported the presentation by recycled but not newly synthesized MHC-II (Fig. 6D ). Significant enhancement of presentation by treatment with cycloheximide suggests that inhibiting MHC-II synthesis enhanced cell surface expression of recycled MHC-II loaded with peptides from intracellular NY-ESO-1. Treatment with selective inhibitors (17-DMAG and radicicol) and siRNA-mediated silencing indicated that the presentation did not require chaperoning by HSP90 ( Supplementary Fig. S3A and S3B ), which played a critical role in the presentation of NY-ESO-1 95-106 to HLA-DR01-restricted TR-CD4 by SK37 (18, 33, 34) . In addition, treatment with PFT-m and quercetin, which inhibit HSP70 chaperoning and stress-induced HSP expression (35, 36) , respectively, enhanced the presentation, suggesting an inhibitory role for HSP70 in this presentation ( Supplementary  Fig. S3A ).
Discussion
In classical antigen-processing pathways, intracellular proteins are not efficiently loaded onto MHC-II for presentation to CD4 þ T cells unless the protein is localized in or targeted to endosomal or lysosomal compartments (37) (38) (39) (40) . Because most immunogenic tumor antigens, including NY-ESO-1, are intracellularly expressed, tumor antigen-specific CD4 þ T cells In the present study, we provide several lines of evidence that indicate the requirements for antigen (NY-ESO-1) specificity and MHC-II (DP04) restriction for direct tumor recognition by TR-CD4. Although both TR-CD4 and NTR-CD4 similarly recognized the 14-mer NY-ESO-1 157-170 vaccine peptide, TR-CD4 efficiently (10 3 -10 4 fold) recognized 9-mer NY-ESO-1 161-169 peptide. The differences in the minimal epitope for TR-CD4 and NTR-CD4 suggest that the unique peptide-TCR interaction is responsible for the tumor-recognizing ability by TR-CD4. Indeed, the sequences of the genes encoding the TCR a and b chains for TR-CD4 and NTR-CD4 are different (ref. 20 and data not shown). A future approach to test whether the TCR is solely responsible for the ability of TR-CD4 to recognize tumor cells will be to retrovirally transduce TCR genes from TR-CD4 and NTR-CD4 into polyclonal expanded T cells and test for the recognition of intracellular NY-ESO-1.
We have characterized the antigen-processing mechanisms for the endogenous MHC-II presentation of intracellular NY-ESO-1 to DR01-restricted NY-ESO-1 95-106 -specific CD4 þ T cells by SK37 (18) . The use of the same cancer cell line (SK37) as well as pharmacologic inhibitors for antigen processing enabled us to directly compare pathways for DR01-and DP04-restricted endogenous MHC-II presentation of intracellular NY-ESO-1. Both presentations were efficiently inhibited by epoxomicin, an inhibitor of proteasome. Interestingly, another proteasome inhibitor, lactacystin, only inhibited DR01-restricted presentation, potentially indicating that there are differences in the enzymatic activities required for the generation of the DR01-and DP04-binding epitopes (25) . The cytosolic proteasome is generally involved in the generation of MHC-I-binding short peptides, which supports our finding that TR-CD4 cells efficiently recognize short 8-9-mer peptides. Both presentations were efficiently decreased by inhibitors for endosomal/lysosomal proteases, indicating that the peptides are loaded on MHC-II in the endosomal or lysosomal compartments.
Although there are multiple shared processing pathways between DR01-and DP04-restricted endogenous MHC-II presentations of intracellular NY-ESO-1, there are also distinct differences. DP04-restricted presentation required TAP-mediated peptide transport into endoplasmic reticulum and endosomal recycling, whereas DR01-restricted presentation required vesicular trafficking through the trans-golgi network and chaperoning by HSP90. As HSP90 is known to facilitate the translocation from endosomal/cytosomal compartments to cytosol (41) , it is likely that HSP90 plays a role in the reverse translocation of proteasome-dependent cytosolic peptides to endosomal/lysosomal compartments for the loading on MHC-II as seen for constitutive HSP70 (HSC70)-dependent chaperone-mediated autophagy (16) . However, in the case of DP04-restricted presentation, the route for the cytosolic peptides to endosomal/lysosomal compartments is yet to be determined. In the classical MHC-I antigen-presentation pathway, peptides generated by the proteasome are translocated into endoplasmic reticulum through TAP and loaded onto MHC-I. Because of the TAP dependency of the DP04-restricted endogenous MHC-II presentation (Fig. 5B) , the DP04-binding peptide is considered to enter the endoplasmic reticulum. We propose that there are two potential mechanisms for the peptide in the endoplasmic reticulum to be loaded onto MHC-II in the endosomal/lysosomal compartments: (i) fusion between endosome/lysosome and endoplasmic reticulum (42) ; and (ii) Figure 5 . Effect of inhibitors for MHC-I antigen-processing pathways on the recognition of SK37 by TR-CD4. A, SK37 was treated by the indicated inhibitors for 16 to 20 hours followed by fixing with paraformaldehyde and extensive washes. SK37 was cocultured for 20 hours with TR-CD4. IFN-g level in the supernatant was measured by ELISA. B, role of TAP in the presentation. Untreated parental SK37 and SK37 clones stably expressing ICP47 gene were used as stimulator cells. GM-CSF level in the supernatant was measured by ELISA. Statistical significance was calculated by the Student t test and is shown as Ã , P 0.05; ÃÃ , P 0.01; and ÃÃÃ , P 0.001.
exchange of MHC-I-and MHC-II-loaded peptides during endosomal recycling (43) . Confirmation of these mechanisms will require the development of sensitive imaging experiments using epitope-specific antibodies to determine the route. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
